Clinical Trial Translation: What ICH GCP and the Regulators Actually Require

The study is funded, the protocol is locked, and the first sites are ready to activate. Then the clinical operations lead opens the country package for Site 014 and finds the thing nobody budgeted for: an informed consent form, a participant information sheet, a diary card, and a recruitment flyer — all in English, all needed in the site’s national language, all sitting in front of an ethics committee that will not schedule a review until they arrive.

This is where trial timelines quietly go sideways. Not in the science. In the language.

If you have lived this, you already know the failure mode is rarely a bad translation. It is a translation that was never planned for, ordered late from whoever was available, and submitted without the documentation an inspector or an ethics committee expects to see behind it.

What does ICH GCP actually say about language?

ICH E6(R3), the revised Good Clinical Practice guideline, reached Step 4 and was adopted on 6 January 2025. The EMA applied it from 23 July 2025, and the U.S. FDA published it as guidance for industry on 9 September 2025. It is now the operating standard sponsors are held to on both sides of the Atlantic.

E6(R3) does not hand you a translation procedure. What it does — and this matters more — is frame informed consent as an ongoing process of understanding rather than a signature event. Information given to a potential participant must be clear, concise, and understandable to that person, and they must be able to ask questions and clarify throughout the trial. A consent form rendered into a language a participant technically reads but cannot follow does not satisfy that standard, no matter how literal the translation is.

The guideline’s broader shift toward quality by design and risk-proportionate thinking applies here too. Participant-facing documents are high-risk by definition: they carry the ethical and legal weight of the study. Your translation process should be proportionate to that risk, and you should be able to show what the process was.

Which U.S. regulations govern translated consent?

Three citations do most of the work.

21 CFR 50.20 requires that information given to a subject or their legally authorized representative be in language understandable to them. That is the root obligation, and it is not satisfied by an English form and a bilingual staff member improvising at the bedside.

21 CFR 50.27(b)(2) provides the short form pathway for a participant who does not read the language of the full IRB-approved consent document. The elements of consent are presented orally, a witness must be present, the IRB must approve a written summary of what will be said, and the signature and copy requirements are specific: the participant signs the short form, the witness signs both the short form and the summary, the person obtaining consent signs the summary, and the participant receives copies of both. It is a legitimate route — but it is a route with paperwork, not a shortcut around translation.

45 CFR 46.116, the Common Rule analogue, carries the same understandable-language requirement for federally supported research and puts key information first in the consent process.

And when the data eventually reaches a marketing application, 21 CFR 314.50(g)(2) requires an accurate and complete English translation of each part of an NDA that is not in English, along with a copy of each original literature publication for which a translation is submitted. The foreign-language documents generated at your sites do not disappear at database lock. They come back.

How does the EU Clinical Trials Regulation change the picture?

Regulation (EU) No 536/2014 splits the dossier. Under Article 26, each Member State determines the language of the application documents, and many accept English for the Part I scientific material — which is why sponsors often assume the language burden is small. It is not, because the participant-facing half is national by design. Informed consent must be given in writing, in terms a lay person can understand, in a language the participant understands, and it is assessed nationally: site by site, ethics committee by ethics committee.

Article 37 adds the obligation that catches sponsors after the trial closes: a summary of trial results written for laypersons, for the countries where the study ran. A plain-language summary is not a translation of the clinical study report. It is a rewrite at a different reading level, then localized — and it is a deliverable most teams discover late.

If you are running a device or diagnostic alongside the therapeutic, labeling and instructions-for-use obligations layer on top. Our medical device translation page covers how those requirements interact with a trial already in flight.

What about patient-reported outcomes and rating scales?

A PRO instrument is not ordinary copy. Its measurement properties depend on each item meaning the same thing to a participant in Warsaw as it does to one in Houston, and a literal translation routinely breaks that. The accepted industry answer is linguistic validation — the process described in the ISPOR task force principles for translating and culturally adapting patient-reported outcome measures: two independent forward translations, reconciliation, back translation, review against the source, and cognitive debriefing with people from the target population, all documented.

The trap is that many instruments are licensed, and the license often specifies who may produce or approve translations and whether a validated version already exists. Commissioning a fresh translation of an instrument that already has an approved one is money spent to create a data-comparability problem.

What does a defensible translation workflow look like?

Here is the plan we run with sponsors and CROs, and it is deliberately boring.

1. Build the language matrix before site activation. Every country, every document type, every required language, with the ethics-committee submission date worked backward. Most translation emergencies are calendar failures, not linguistic ones.
2. Separate the document tiers. Participant-facing material (consent forms, information sheets, diary cards, recruitment) needs the highest rigor and ethics review. Instruments need licensed linguistic validation. Site-facing and regulatory material needs accuracy and traceability. Treating all three the same either overspends or underprotects.
3. Use subject-matter linguists with a second-linguist review. Life sciences work is not a place for a single pass. Taika’s process meets and exceeds ISO 17100, 9001, and 27001 standards, and every life sciences project runs translation plus independent revision by a second qualified linguist.
4. Keep the audit trail. Translator qualifications, the revision record, the certification statement, version control against the source. When an inspector asks how you know the Polish consent form matches the approved English, the answer should be a file, not a memory.
5. Plan for amendments. Protocols change. A translation memory maintained across the study means amendment four costs a fraction of the original and stays consistent with amendments one through three.

Our clinical trial translation service is built around exactly that sequence, and the broader life sciences translation practice covers the regulatory, safety, and manufacturing documents that sit on either side of the trial itself. Confidentiality is handled the same way throughout — the controls described in our guide to HIPAA-compliant medical translation apply to trial data and participant material alike.

Where do sponsors most often get caught?

Four places, consistently. Recruitment material translated but never submitted for ethics review. A short form used as a standing substitute for a translated consent rather than as the documented exception it is. Site-generated source documents — worksheets, clinician notes, adverse event narratives — created in the local language with no plan for the eventual English translation. And lay summaries scoped at the last minute, after the team has moved on to the next study.

None of these are hard problems. They are all planning problems, and they are all cheaper to solve twelve months early than four weeks late.

Ready to get your study package translated properly?

Bring us the language matrix — or bring us the protocol and let us build one with you. We will scope every document tier, flag the licensed instruments that need validated versions, and give you a schedule that lines up with your ethics submissions instead of chasing them.

Our accuracy commitment covers the quality of the translation itself: if a document we certify is rejected for translation quality, we correct it. We make no promises about regulatory outcomes, and you should be skeptical of any language provider who does.

Request a quote for your trial package, or read more about how our clinical trial translation team works with sponsors, CROs, and site networks.